INC Research Appoints Hans J. Moebius as Senior Vice-President of CNS Division for Europe
27 February 2007
INC Research, a therapeutically focused contract research organization with a trusted process for delivering reliable results, has named Hans J. Moebius, M.D., Ph.D., as senior vice-president of its Central Nervous System (CNS) business for Europe. In this position, Dr. Moebius will be responsible for the operations, strategic planning and corporate development of INC Research's European CNS business and will have management oversight for all CNS and pediatrics research staff and clinical trials taking place in Europe.
Dr. Moebius will also oversee INC Research's expansion into Switzerland and will serve as head of the INC Research Zurich office, which opens in January 2007. Dr. Moebius has more than 16 years of strategic drug development experience in Europe, the United States and Japan, and he has personally overseen the development of NCEs in epilepsy, Parkinson's disease, depression, Alzheimer's disease and vascular dementia, ADHD, spasticity, neuropathic pain, chronic pain, and addiction.
He has worked with the FDA, EMEA and several national authorities for the successful registration of five new CNS therapies including all aspects of pre-clinical and clinical development, regulatory strategy and establishing global pharmacovigilance strategies. Dr. Moebius will play a leading role in INC's Product Development Services (PDS) group, providing CNS drug development consultancy to INC's pharmaceutical customers.
"Dr. Moebius is an exceptional addition to our international CNS team", said Kelvin Logan, Ph.D., president of INC Research, Europe. "As we look to further solidify and expand our presence within the European CRO market, Dr. Moebius' substantial clinical and management expertise will be extremely beneficial in continuing to establish INC Research as an industry leader globally."
Before joining INC Research, Dr. Moebius served for 10 years with Merz Pharmaceuticals, for the last five years as chief scientific officer and managing director. He was responsible for the supervision of seven different departments and hundreds of employees, establishing the company's CNS drug development pipeline and managing international drug development programs and partnerships. Prior to that, he served for five years as senior vice-president, global research and development and drug regulatory affairs.
Dr. Moebius has won a number of professional distinctions, including heading up the team that won the German Industry Innovation Award for the international development of memantine in late-stage Alzheimer's disease (2002).
He is currently a member of the European College of Neuropsychopharmacology, the German Society of Pharmaceutical Physicians, the American Academy of Neurology and the German Society for Neurology. He has participated in the international working group for the development of anti-dementia guidelines and is a founding member of the American Society for Experimental Neurotherapeutics and the Swiss Association of Pharmaceutical Physicians.
Dr. Moebius earned a bachelor's of science degree in chemistry from the University of Kaiserslautern and a doctorate degree in experimental pharmacology from the University of Heidelberg. He is a board-certified psychiatrist and neurologist who completed his medical studies at the Universities of Heidelberg and Frankfurt in Germany. He holds the Swiss degree in pharmaceutical medicine.
